相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。被撤回的出版物: The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo (Retracted article. See vol. 134, pg. 95, 2019)
Girija Dasmahapatra et al.
BLOOD (2010)
The NF (Nuclear factor)-κB inhibitor parthenolide interacts with histone deacetylase inhibitors to induce MKK7/JNK1-dependent apoptosis in human acute myeloid leukaemia cells
Yun Dai et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
A Functional Receptor for B-Cell-Activating Factor Is Expressed on Human Acute Lymphoblastic Leukemias
Reshmi Parameswaran et al.
CANCER RESEARCH (2010)
Romidepsin and Belinostat Synergize the Antineoplastic Effect of Bortezomib in Mantle Cell Lymphoma
Luca Paoluzzi et al.
CLINICAL CANCER RESEARCH (2010)
Histone Deacetylase Inhibitors Activate NF-κB in Human Leukemia Cells through an ATM/NEMO-related Pathway
Roberto R. Rosato et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair
J-H. Lee et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
The BH3-only protein Bim plays a critical role in leukemia cell death triggered by concomitant inhibition of the PI3K/Akt and MEK/ERK1/2 pathways
Mohamed Rahmani et al.
BLOOD (2009)
Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma
Ashraf Badros et al.
CLINICAL CANCER RESEARCH (2009)
Bim Upregulation by Histone Deacetylase Inhibitors Mediates Interactions with the Bcl-2 Antagonist ABT-737: Evidence for Distinct Roles for Bcl-2, Bcl-xL, and Mcl-1
Shuang Chen et al.
MOLECULAR AND CELLULAR BIOLOGY (2009)
Bim-targeted cancer therapy: A link between drug action and underlying molecular changes
Toru Akiyama et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate
Yun Dai et al.
BLOOD (2008)
Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia
Guillermo Garcia-Manero et al.
BLOOD (2008)
Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells
Yun Dai et al.
CLINICAL CANCER RESEARCH (2008)
Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia
Eyal C. Attar et al.
CLINICAL CANCER RESEARCH (2008)
Proteasome inhibitors in cancer therapy: Lessons from the first decade
Robert Z. Orlowski et al.
CLINICAL CANCER RESEARCH (2008)
Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes
Guillermo Garcia-Manero et al.
BLOOD (2008)
The histone deacetylase inhibitor, PXD101, potentiates bortezomib-induced anti-multiple myeloma effect by induction of oxidative stress and DNA damage
Rentian Feng et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Frequent engagement of the classical and alternative NF-κB pathways by diverse genetic abnormalities in multiple myeloma
Christina M. Annunziata et al.
CANCER CELL (2007)
NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells
Claudia P. Miller et al.
BLOOD (2007)
A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: A Children's Oncology Group study
Terzah M. Horton et al.
CLINICAL CANCER RESEARCH (2007)
Targeting the NF-kappa B signaling pathway in Notch1-induced T-cell leukemia
Tomas Vilimas et al.
NATURE MEDICINE (2007)
IκB kinase complexes:: gateways to NF-κB activation and transcription
Claus Scheidereit
ONCOGENE (2006)
Aggresome disruption: A novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells
ST Nawrocki et al.
CANCER RESEARCH (2006)
Molecular linkage between the kinase ATM and NF-κB signaling in response to genotoxic stimuli (Publication with Expression of Concern. See vol. 371, pg. 1002, 2021)
ZH Wu et al.
SCIENCE (2006)
Anticancer activities of histone deacetylase inhibitors
Jessica E. Bolden et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Acetylation and deacetylation of non-histone proteins
MA Glozak et al.
GENE (2005)
Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim
Y Zhao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90 - A novel basis for antileukemia activity of histone deacetylase inhibitors
P Bali et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-κB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-jun n-terminal kinase 1 activation
Y Dai et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma
T Hideshima et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies
KN Bhalla
JOURNAL OF CLINICAL ONCOLOGY (2005)
Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors
JS Ungerstedt et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Induction of p100 processing by NF-κB-inducing kinase involves docking IκB kinase α (IKKα) to p100 and IKKα-mediated phosphorylation
GT Xiao et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors
XY Pei et al.
CLINICAL CANCER RESEARCH (2004)
Phase I study of bortezomib in refractory or relapsed acute leukemias
J Cortes et al.
CLINICAL CANCER RESEARCH (2004)
The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571
CR Yu et al.
BLOOD (2003)
Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-κB-dependent process
Y Dai et al.
ONCOGENE (2003)
Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation
SJ Haggarty et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo
Y Zhang et al.
EMBO JOURNAL (2003)
Preferential induction of apoptosis for primary human leukemic stem cells
ML Guzman et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Acetylation of ReIA at discrete sites regulates distinct nuclear functions of NF-κB
LF Chen et al.
EMBO JOURNAL (2002)
NF-κB as a therapeutic target in multiple myeloma
T Hideshima et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Nuclear factor-κB is constitutively activated in primitive human acute myelogenous leukemia cells
ML Guzman et al.
BLOOD (2001)
Duration of nuclear NF-κB action regulated by reversible acetylation
LF Chen et al.
SCIENCE (2001)
Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli
Y Yang et al.
SCIENCE (2000)
分享论文
